Microbot Medical Inc MBOT 深 滬
已收盤 08-22 16:00:00 美东时间
3.85
+0.290
+8.15%
華盛通- 最 高3.94
- 今 開3.59
- 成交量 553.76万股
- 最 低 3.52
- 昨 收 3.56
- 總市值 1.40亿
- 52周最高 3.94
- 市盈率 靜 --
- 換手率 15.22%
- 52周最低 0.82
- 委 比 58.24%
- 總股本 3637.78万
- 歷史最高 149.10
- 量 比 1.79
- 振 幅 11.80%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多US Patent And Trademark Office Grants Microbot Medical Patent Covering Modular Robotic Surgical System Includes Base And Plurality Of Tool-Receiver Units Arranged As Separate Units And Independently And Interchangeably Attachable To Base
With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending.The Company Continues to Scale Commercial Readiness
08-20 20:40
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
Microbot Medical Inc. has received a new U.S. patent for its LIBERTY® Endovascular Robotic System, which now boasts 12 granted patents globally and 57 pending applications. The patent covers a modular robotic system, enhancing its adaptability for broader endovascular procedures, potentially expanding its Total Addressable Market (TAM). With this innovation, the company aims to address over 6 million annual U.S. endovascular procedures. Microbot ...
08-20 12:30
Microbot Medical Q2 EPS $(0.10) Misses $(0.08) Estimate
Microbot Medical (NASDAQ:MBOT) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 41.18 percent increase over losses of $(0.17) per share from
08-13 05:53
Microbot Medical Announces It Will Receive A Non-Dilutive Grant From The Israel Innovation Authority In The Amount Of $630K
Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA") in
08-05 20:35
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
Microbot Medical Inc. has been granted NIS 2.15 million (~$630,000) by Israel Innovation Authority to strengthen its manufacturing capabilities and prepare for the commercialization of the LIBERTY® Endovascular Robotic System, pending FDA clearance. Recognizing the company's milestones and competitive advantages, the grant reflects confidence in its ability to scale operations and meet business objectives as it awaits regulatory approval.
08-05 12:30
Microbot Medical Appoints New VP of Sales
An announcement from Microbot Medical ( ($MBOT) ) is now available. On July 22,...
07-22 20:58
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Microbot Medical appoints Christina Bailey as VP of Sales, leveraging her 20 years of experience in medical device sales and leadership. Bailey, a two-time Olympian, brings expertise from companies like Boston Scientific and Intuitive Surgical, and will support the anticipated launch of the LIBERTY Endovascular Robotic System. The system is currently investigational and awaiting FDA clearance.
07-22 12:30
Microbot Medical Boosts Finances with Stock Issuance
An update from Microbot Medical ( ($MBOT) ) is now available. Microbot Medical ...
07-18 05:32
Microbot Medical Showcases Robotics at Strasbourg Event
The latest announcement is out from Microbot Medical ( ($MBOT) ). On July 8, 20...
07-08 20:59
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Microbot Medical Inc. will participate in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France, from July 16-20. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will discuss emerging technologies in peripheral vascular, neurovascular, and cardiovascular spaces. Harel Gadot, the Company’s Chairman, CEO, and President, will present an overview of...
07-08 12:30
